Jubilant Pharmova Limited announced that the USFDA has approved commercial batch manufacturing on Line 3 at its Spokane facility. The approval covers the first product on the new isolator-based fill and finish line.

The regulatory clearance was received on August 21, 2026, at 12:46 pm PST, corresponding to August 22, 2026, at 1:16 am IST. The company disclosed the development in a filing with stock exchanges on August 23, 2026.

Facility Details

Line 3 is located at the contract manufacturing facility of Jubilant HollisterStier LLC in Spokane, Washington. This subsidiary operates under Jubilant Pharma Holding Inc., which is part of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova.

Capacity Expansion

The new line is an isolator-based fill and finish unit designed for sterile injectables. Jubilant HollisterStier specializes in sterile injectables, including liquid and lyophilized products, as well as ophthalmic formulations such as ointments, liquids, and creams.

The approval enables the facility to process commercial batches for its first product on this specific line. The company provides end-to-end manufacturing support, ranging from process qualifications to commercial release.

Business Context

Jubilant Pharma Limited operates across multiple segments, including radiopharmaceuticals, allergy immunotherapy, and contract manufacturing. The company maintains a network of 45 radiopharmacies in the US and employs approximately 3,200 people globally. Its manufacturing facilities cater to regulated markets in the US, Europe, and other regions.

Jubilant Pharmova’s broader portfolio includes contract research and development, generics, and proprietary novel drugs. The group employs around 5,500 people worldwide and serves customers in over 75 countries.

Shareholders of Jubilant Pharmova have approved the re-appointment of its top leadership, including Managing Director Mr. Priyavrat Bhartia and Joint Managing Director Mr. Arjun Shanker Bhartia, along with their respective remuneration packages. The approvals were secured via a postal ballot process that concluded on August 17, 2026.

The company disclosed the outcome pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both special resolutions received overwhelming support from the promoter group and public shareholders, reflecting strong confidence in the existing management structure.

Voting Results

The postal ballot was conducted through remote e-voting on the National Securities Depository Limited (NSDL) platform. The voting window opened on July 19, 2026, and closed on August 17, 2026. As of the cut-off date of July 10, 2026, there were 83,910 registered shareholders.

Re-appointment of Managing Director

The resolution to re-appoint Mr. Priyavrat Bhartia as Managing Director was passed with significant majority support. Promoter and promoter group shareholders voted unanimously in favor, holding 75,938,622 shares. Public institutional shareholders also showed strong support, with 99.41% of polled votes in favor.

Re-appointment of Joint Managing Director

Similarly, the resolution to re-appoint Mr. Arjun Shanker Bhartia as Joint Managing Director received near-unanimous approval. The promoter group again voted 100% in favor. Among public institutions, 99.61% of votes were cast in support, while public non-institutions showed 99.98% support.

Scrutinizer’s Report

Rupinder Singh Bhatia, a practicing Company Secretary, served as the independent scrutinizer for the postal ballot process. The scrutinizer confirmed that the remote e-voting process was conducted fairly and transparently in compliance with the Companies Act, 2013, and SEBI LODR Regulations. The e-voting system was monitored through a secured link provided by NSDL, and the process was unblocked in the presence of two independent witnesses after the deadline.

The company noted that promoters and the promoter group had no interest in either agenda item. The detailed voting results and the scrutinizer’s report are available on the company’s website and the NSDL e-voting portal.